CD274 and neoplasm: Our findings are in line with recent studies showing that tumor cells upregulate PD‐L1 to escape the cytotoxicity of CAR‐T therapy[12, 13] and that tumor‐infiltrated CAR‐T cell exhaustion is associated with increasing levels of PD‐1 (PD‐L1 receptor) on effector cells and PD‐L1 in the TME.[12, 13, 14, 15, 16] Consequently, the development of combined treatment strategies of PD‐L1/PD‐1 blockade and CAR‐T therapy has been reported.[12, 13, 16]